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A B S T R A C TThis article aims to provide an overview of the current literature
focusing on the reimbursement of personalized medicine across the
European Union. The article starts by describing types of perspectives
that are possible (general public, patient, payer, provider, service
commissioner, and policymaker). The description of perspectives also
explains the importance of understanding the different possible
decision criteria and processes from the various perspectives by
taking into account budget constraints. The article then focuses on
an example of personalized medicine, namely, the use of companion
diagnostic-medicine combinations, to describe the role of reimburse-
ment/payer agencies across the European Union to control thesee front matter Copyright & 2013, International S
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Floor, Jean McFarlane Building, Oxford Road, Manintroduction and coverage of such companion diagnostic-medicine
technologies. The article touches on the strategic challenges and the
use of economic evidence to introduce personalized medicine from a
health policy perspective. The article also draws on empirical studies
that have explored patients’ and clinicians’ views of examples of
personalized medicine to illustrate the challenges for developing
patient-centered and timely health care services.
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Personalized medicine is moving away from being a hyped
theoretical concept to applications used in clinical practice.
Speciﬁcally, personalized medicine is becoming a practical reality
with the targeting of medicines by using a biomarker or genetic-
based diagnostic to identify the eligible patient population. To
date, the most common applications are the targeting of cancer
medicines by using knowledge of pharmacogenomics to develop
companion diagnostic-medicine combinations [1]. There are also,
however, some clinical examples of using a person’s genotype to
target the safe use of medicines, such as thiopurine methyl-
transferase (TPMT) testing in patients treated with azathioprine
[2], in noncancer conditions such as autoimmune diseases. At the
moment, the available diagnostic technologies aim to detect a
single biomarker or variant in a single gene, but new next
generation and whole genome sequencing technologies will soon
make genomic proﬁling of tumors or individuals a practical
reality in common practice. Although true advances in science
that lead to clinically useful applications are to be welcomed, it is
clearly necessary to take account of the context in which new
technologies are introduced into practice. The global economic
climate is putting greater emphasis on the need to effectively use
ﬁnite, and often limited, health care budgets.
There is substantial diversity in how health care systems are
provided and funded across European countries [3]. There is acommonality, however, in the need for decision makers working
within these health care systems at local, regional, or national
levels to think about how best to spend the available health care
budget effectively. Ideally, the decision makers want a sufﬁ-
ciently robust evidence base to reassure them that they are
spending the resources in the best way possible. This need for
information presented as a structured evidence base has stimu-
lated the development of funding streams, dedicated organiza-
tions, and processes to produce health technology assessments
(HTAs). The general concept of an HTA—“a multidisciplinary
process that summarises information about the medical, social,
economic and ethical issues related to the use of a health
technology in a systematic, transparent, unbiased, robust man-
ner” [4]—is well described and generally accepted. Best practice
guidance has also emerged [5]. There is substantial variation,
however, across Europe in the process of funding and producing
HTAs, the technical details used in the evaluative methods, and
the intended use of the HTA reports [6]. HTAs can potentially be
used to inform clinical guidelines or reimbursement decisions for
local, regional, or national use. In some jurisdictions, HTAs have
a more formal legal status and are used by national decision
makers working for third-party health care payer organizations.
In England, there are national HTA processes in place, led by the
National Institute for Health Research Evaluation, Trials and
Studies Coordinating Centre, selecting and targeting the funding
of assessments of speciﬁc technologies. The HTAs are used byociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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but selected reports are subsequently used by the National
Institute for Health and Care Excellence (NICE) in the appraisal
of health care technologies and public health interventions and
programs to inform recommendations published as national
guidance. In Belgium, there is a dual track. In one track,
diagnostic tests for which reimbursement is claimed by the
manufacturer undergo a process and a judgment by a technical
commission within the National Institute for Health and Dis-
ability Insurance on the basis of unclear criteria; and in a second
track, the Belgian HTA body “KCE” can select speciﬁc diagnostic
tests to perform a full HTA. In other countries, such as Greece,
there are no dedicated HTA organizations and no economic
evidence is used to inform reimbursement decisions or guideline
development [7].
The concept of personalized medicine is being introduced into
health care systems working with this varied backdrop of HTA
funding, design, and use across Europe. Another layer of varia-
tion occurs if the type of technology is more carefully considered,
and different processes may exist within countries for different
types of technologies. Companion diagnostic-medicine combina-
tions could potentially be the Holy Grail of payers and reimburse-
ment agencies because they allow a clinician to predict who will
respond and how they will respond before a medicine is pre-
scribed and any money is spent. Furthermore, patients could
favor targeted medicines because they will be more likely to be
offered an effective and safe medicine with a good chance of
relieving symptoms or curing disease. Using the theory of
personalized medicine to develop a companion diagnostic test
means that populations are stratiﬁed into subgroups such that
only patients identiﬁed as having a high probability of respond-
ing well are offered treatment. By deﬁnition, however, the
combination technology is now two technologies that are linked
but distinct. They are distinct in terms of the scientiﬁc knowledge
needed to develop them into a clinical application, the evidence
base needed to license the technology, and the system for setting
the price of the product, and in terms of the requirement for, and
type of, reimbursement/payer systems in place. Garrison and
Austin [8] succinctly point out the difference in resource- or cost-
based approaches to setting the price of a diagnostic compared
with a broad value-based system for medicines.
The variation in the evidence base available for a diagnostic
compared with a medicine has potentially emerged because of
the perception in different types of potential harms and the risk
associated with a particular technology. The entry of a new
pharmaceutical into the market is highly controlled, with a need
for robust evidence on the efﬁcacy, safety, and quality of the
product. Diagnostic tests are viewed to have lower risks in terms
of causing immediate and direct harm from the use of the
product, which is reﬂected in the “risk category” they have been
assigned by regulatory agencies. This does not acknowledge,
however, the potential long-term, or indirect, harms, which could
result from a diagnostic that provides clinicians with probabilistic
rather than a deﬁnitive answer, and the impact on patient
morbidity and mortality associated with false-negative or false-
positive test results. Taking account of the regulatory backdrop is
important when considering if, and how, reimbursement and
payer decisions are then informed and made. The regulatory
system will drive the evidence base for the available future HTA
and consideration of whether the technology offers added bene-
ﬁts in terms of its clinical effectiveness and cost-effectiveness
compared with current practice [9]. Faulkner et al. [10] acknowl-
edge the roles of two key players involved in producing and using
the evidence base: the manufacturers and the payers. In their
article, Faulkner et al. echo the broad recommendations of
Meckley and Neumann [11], who suggest a need for manufac-
turers to generate a stronger better clinical evidence base toprove the added value and clinical utility of their companion
diagnostic-medicine product. Faulkner et al. [10] add to the
literature by describing ﬁve key areas requiring development to
produce the evidence base necessary to support the introduction
of personalized medicine into clinical practice, including the
need to harmonize the processes for diagnostics and medicines.
This view was supported by Fugel et al. [12], who acknowledge
the difference in pricing and reimbursement frameworks
between diagnostics and medicines within and across European
countries as a result of case-by-case assessment of diagnostic
tests at the local or regional level.
This article aims to add to the current literature on how best
to meet the challenge of ensuring appropriate market access for
personalized medicines by suggesting the need for a strategic
approach to reimbursement across Europe. The article starts by
describing types of perspectives that are possible. The description
of perspectives will also explain the importance of understanding
the different possible objective functions from the various per-
spectives taking into account budget constraints. The article
delineates the challenge of taking a strategic approach, and the
use of economic evidence, to introduce personalized medicines
from a health policy perspective. The article also draws on
empirical studies that have explored patients’ and clinicians’
views of examples of personalized medicine to illustrate the
challenges of developing patient-centered and timely health care
services. The article concludes with recommendations for
improving the evidence base for reimbursement/payer agencies
charged with controlling the introduction of companion
diagnostic-medicine technologies within Europe.
Reimbursement of Personalized Medicines: Whose
Perspective?
Taking an economists’ view of the world, it is important to be
explicit whose perspective is being considered and which eval-
uative framework should be used to inform the reimbursement of
technologies such as companion diagnostic-medicine combina-
tions. Previous authors, such as Beitelshees and Veenstra [13],
have already deﬁned some key perspectives to consider in the
context of personalized medicine from a US viewpoint, including
the federal government, the science-based clinical academic
community, the pharmaceutical industry, managed care organ-
izations, and pharmacy beneﬁts managers, clinicians, and
patients. Similar perspectives can be deﬁned relevant to a health
care market for personalized medicines in the European context.
The divide between supply and demand in a health care market
is not always distinct. Given the need to identify who might be
responsible for meeting the burden of proof in terms of showing
the added value of companion diagnostic medicines, it is useful
to deﬁne perspectives as being predominantly that of a supplier
or user of health care. Implicit in this statement is the assump-
tion that it is the suppliers of health care who are responsible for
providing evidence of added value for a new technology. Table 1
lists some key potential perspectives and deﬁnes them as
suppliers or users of personalized medicine.
Table 1 illustrates how a number of stakeholders in the
health care system have a duality of roles, acting as suppliers
and users of health care technologies such as personalized
medicine. This means that the stakeholder may also have to be
ﬂexible in terms of whether they are suppliers or users of an
evidence base that supports or refutes the added value of a
companion diagnostic medicine. Understanding different per-
spectives is useful to identify how there are potentially differ-
ent objectives and associated budget constraints, which will
affect the incentives for a provider to produce the required
evidence base and a potential user to take up a new technology.
Society, made of current and future patients, represented by the
Table 1 – Key perspectives and roles in the market
for personalized medicines.
Supplier Supplier and user User
Academic community
(science and applied
research)
Government (health
policy makers)
Society
Manufacturer
(pharmaceutical and
diagnostic)
Third-party health care
payers
General
public
Private laboratories
(molecular and
pathology)
Health service
commissioners
(national, regional,
local)
Patients
Hospital-based
laboratories
(molecular and
pathology)
Reimbursement and
drug formulary
committees
Hospital-based
pharmacy services
Clinicians (primary care,
general, and specialist
hospital)
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clear role as receivers of information and user of a health care
service and associated technologies. A society will establish a
system for providing a research environment and health care
service and identifying approaches to funding public services by
voting for a government. Society as a whole may be interested
in maximizing population well-being, which may include
health and nonhealth aspects of quality of life. Decision makers
involved in forming policy to guide funding allocation or
providing guidance for the development of clinical guidelines
generally use evidence of clinical effectiveness and cost-
effectiveness because of their objective to maximize the health
of the patient population. This evidence base is used to inform
normative judgments about what should be done in terms of
spending a health care budget. The cost-effectiveness evalua-
tive framework assumes an extra-welfarist view to inform what
constitutes a beneﬁt, which has led to “health” as the targeted
outcome. In terms of practical decision making, this means that
evidence of cost-effectiveness is often summarized as the
incremental cost per quality-adjusted life-year or life-year
gained [14]. This implies that, in general, payers and reimburse-
ment agencies focus on proposed beneﬁts in terms of health
gain. From some perspectives, valuing health gain alone may be
deemed insufﬁcient in terms of capturing all the potential
beneﬁts or added value of personalized medicines. Manufac-
turers may want more than health gain to be included in the
proposed system of value-based pricing to adequately reﬂect
the beneﬁt associated with the information from using a test to
more accurately predict the eligible population of good res-
ponders to a medicine. The obvious objective of a manufacturer
is to maximize company proﬁts, which will be set by the income
from sales. At a societal level, the information from a compan-
ion diagnostic will potentially enable reduced waste of scarce
resources by averting the use of expensive medicines in
patients who will not respond. Note that these potential savings
are included in the incremental cost per quality-adjusted life-
year approach, whereby the incremental cost is the net result of
the investment in the personalized approach (e.g., the cost of
the test) minus the potential savings. The main difference
between a full societal perspective and a more limited NHS or
health insurer perspective is that productivity-related costs are
not included in the latter. At the individual level, both clinicians
and patients may be reassured by the additional information,
even though probabilistic, from a test to more accurately targeta medicine. The clinician may feel more certain that he or she
has selected the right treatment for that patient. Similarly,
patients may feel that they are being offered the best treatment
for them and gain reassurance that the companion diagnostic
test has provided additional information to help the selection of
their treatment. There is some evidence to support that clini-
cians and patients do perceive potential beneﬁts in terms of
both health gain and added value from information [15].
Moving from Market Entry to Achieving Patient Beneﬁt
In addition to understanding the implications of different stake-
holder perspectives when moving a new technology from the
laboratory to achieving beneﬁt in the patient population, it is
necessary to think about the different levels of decision making
that will be encountered along this journey. For medicines, an
obvious hurdle to clear is achieving the approval of the relevant
regulatory committee to allow entry of the pharmaceutical
product onto the health care market. The same hurdle, in general
terms, is also relevant to a companion diagnostic but the
speciﬁcs, in terms of processes and evidentiary requirements,
of gaining market entry are completely different from those for a
pharmaceutical product. Even though once a companion
diagnostic medicine is deemed to be sufﬁciently efﬁcacious to
be granted a product license regulation, there are still three levels
of decision making for gaining “market access” so that patients
can beneﬁt from personalized medicine. These three levels of
decision making are perhaps most usefully described in relation
to the organization of health care delivery: national (centralized),
provider (hospital or primary care), and patient-clinician level. It
is likely that decisions made at each of these three levels may
have different requirements in terms of what evidence base is
considered useful and sufﬁcient for informing choices on
whether to provide a companion diagnostic medicine.
National Centralized Decision Making
All societies vote in a government, which is then generally
responsible for the provision of a health care system. The degree
of centralization in such national health care systems varies
between countries, and there is a balance between national-level
and regional-level decision making in terms of allocating the
health care budget for the patient population. Basically in the
context of personalized medicine, the key question to answer is
the same for regional-level or national-level decision making: Is
the evidence base supporting the use of a companion diagnostic
medicine at the population level sufﬁcient to convince payers or
decision makers in charge of health care budgets to reimburse?
The evidence required at a national level is whether the addition
of a companion diagnostic to target a medicine results in
sufﬁcient added value, in terms of health beneﬁts, given the
cost compared with current practice. In some contexts, the
process of using evidence to inform resource allocation deci-
sions is well structured, especially for the evaluation of the
clinical effectiveness and cost-effectiveness of pharmaceuticals.
The appraisal process set up by NICE in the United Kingdom has
become the gold standard for using evidence of clinical effec-
tiveness and cost-effectiveness to inform national guidelines,
which are subsequently used by decision makers to choose how
best to spend the NHS budget at a regional level. The role of
NICE has now expanded to include the assessment of diagnos-
tics [16]. The remit of the NICE Diagnostic Assessment Pro-
gramme (DAP) is to focus on diagnostics that have a CE mark
(Conformité Européene, which literally means European Con-
formity). The requirement for a CE mark for appraisal by NICE,
by deﬁnition, excludes many examples of companion diagnostic
tests provided by hospital laboratories with quality assurance
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however, has partly recognized this by creating discrete proc-
esses for different “types” of diagnostics that may be used in the
context of personalized medicine. Companion diagnostic med-
icines will be directed, via a Department of Health–led scoping
process, through the NICE Technology Appraisal (TA) route. The
evidence focus for this route is proving to be the added value of
the medicine component of the combination rather than the
predictive value of the diagnostic in selecting the eligible
population. In contrast, diagnostics that have a CE mark and
may be viewed as being additions to a current treatment path-
way or available for use with multiple medicines, such as
epidermal growth factor receptor (EGFR) tyrosine kinase muta-
tion testing in adults with locally advanced or metastatic non–
small-cell lung cancer, are the remits of the DAP. Diagnostic
tests are directed to the attention of the DAP by the manufac-
turer of the product. With the current NICE TA process and the
clinical guideline development process, there is clear scope for
the overlap of the work of the TA program and the DAP. These
two programs, however, have their own methods of selecting
products for assessment, appraisal decision-making commit-
tees, and methods guide informing the required evidence base
for decision making.
In other European countries, there is limited overlap between
reimbursement processes for medicines and diagnostics. In the
United Kingdom, NICE is attempting to deal with the challenge of
trying to evaluate products that do not have like-for-like regu-
latory evidence requirements, such as CE-marked and bespoke
laboratory tests. Some countries such as Belgium, France, The
Netherlands, Italy, and Baltic countries, however, still have
completely unlinked processes, which makes the evaluation of
the clinical effectiveness and cost-effectiveness of a companion
diagnostic challenging. It is not controversial to suggest that it
cannot be an effective use of the time and expertise of decision
makers allocating health care resources by having two processes
for the components of one health care technology. Two distinct
processes means it becomes necessary to have two routes for
providing the evidence base: making a decision and then imple-
menting the outcome of the decision in a complex health care
system.
On a practical level, the process for producing an evidence
base by using a national-level HTA system can also be compli-
cated by having distinct processes for diagnostics and medicines.
Current HTA processes work well for medicines, and there are
multiple examples of how robust HTAs have been used by payers
or used to inform reimbursement decisions. In general, the
process of producing an HTA report is the same for a diagnostic
and a medicine. There are clear nuances, however, in the
technicalities of identifying and producing a summary of the
clinical and economic evidence base suitable for decision making
[17]. In a recently completed report for the European Commis-
sion, a consortium of European researchers (HISCREENDIAG)
reported large diversity in the processes and criteria for decision
making on genetic screening (among which the screening within
a personalized medicine approach). The report will be available
on the Web site of the Department of Public Health of Ghent
University (www.publichealth.ugent.be).
Looking at published HTAs of an example companion
diagnostic-medicine technology—a pharmacogenetic test called
CYP2D6, the practical challenge of producing an economic model
populated with sufﬁciently robust data is exempliﬁed. Fleeman
et al. [18,19] produced two HTA reports looking at applications of
CYP2D6 testing for two pharmaceutical treatments: antipsy-
chotics for people with schizophrenia and tamoxifen for women
with breast cancer, respectively. In both HTAs, the most startling
conclusion was the impact of the limited clinical evidence base to
inform an economic model and the difﬁculty in differentiatingbetween evidence of no effectiveness rather than no evidence of
effectiveness of CYP2D6 testing in these applications. This lack of
evidence of clinical utility and cost-effectiveness remains the
enduring challenge for national centralized decisions to support
the use of personalized medicines in clinical practice.
Provider-Level Decision Making
Even though the challenge of proving evidence of the added value
at a national population level has been met, there is still the issue
of getting the technology introduced and embedded into local
hospital and community services. In some ways, the evidence
base required at the provider level can be viewed to be similar to
that necessary to inform national-level decision making but there
are slight nuances in how evidence of clinical effectiveness and
cost-effectiveness is used by decision makers. It should also be
noted that in some systems, such as Belgium, once a test is
covered at a central level it no longer has any ﬁnancial implica-
tions at the hospital level (it is considered as a pass-through cost),
which makes further assessment on that level less necessary. If
the assessment is required at the provider level, decision makers
working at that level require speciﬁc information on the potential
impact of introducing a new companion diagnostic medicine
from their perspective. This combination technology will have
implications for laboratory and pharmacy departments. It will be
necessary for hospital managers to understand which budgets
will be affected by introducing the companion diagnostic medi-
cine taking into account the local arrangement for ﬁnancing
laboratory and pharmacy services and being clear who is respon-
sible for each respective budget. Introducing a new technology
has an opportunity cost, and provider-level managers are acutely
aware of this and recognize the need for information on areas in
which costs will be saved or reallocated. An issue that is
particularly relevant for new companion diagnostics is the
potential impact of introducing a new technology into a health
care system on the capacity to provide the test and associated
service requirements.
A typical example is one that was observed in the Belgian
context, whereby EGFR testing was required for having a treat-
ment for metastatic colorectal cancer, such as cetuximab, to be
reimbursed, but the EGFR testing itself was not covered and the
local pathologists were not paid for their testing activity either
(nowadays the KRAS test is required and reimbursed).
Clinician-Patient–Level Decision Making
Following local support for a companion diagnostic medicine at
the hospital level for patient beneﬁts to be realized, prescribing
clinicians still have to take up the availability of personalized
medicine and use information from the test. Subsequent to
clinicians’ involvement, patients are expected to follow the
recommendations of the prescribing clinician as implied by the
shared clinical decision-making–level model. At the clinician-
patient–level, in addition to robust data on clinical effectiveness,
other types of evidence is required to support the use of a
companion diagnostic test. Once the concept of a companion
diagnostic medicine is conceived for potential use in clinical
practice, the most immediate information needed is what will be
the potential demand for the test, from both the clinician and the
patient perspective. Clearly, a demand for a companion diagnos-
tic will affect whether, and how, models of service delivery are
established and the potential budget impacts the new technol-
ogy. Information on the potential demand for a companion
diagnostic must then be supported by subsequent information
on the actual uptake of the technology: how it is used in the
clinical management of patients and impact pathways of care. An
important type of information is to have a clear understanding
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target a medicine based on the result of the diagnostic and
impact on prescribing behavior. In general, however, there is a
paucity of evidence to support whether, and how, clinicians use
the results of companion diagnostics and how the test results
affect subsequent prescribing and medicine-taking behavior.
The importance of considering the impact of evidence about
this level of decision making can be illustrated by using the
ﬁndings from a prospective pragmatic randomized controlled
trial (RCT) of a pharmacogenetic test, the TMPT test, to predict
the risk of neutropenia from azathioprine used to treat auto-
immune conditions (the TARGET study). Newman et al. [20]
report the results of this trial, which was pragmatic in design in
that the intervention was the TPMT genotype result and asso-
ciated advice in the form of a clinical report to clinicians
suggesting the appropriate azathioprine prescription and the
comparator was the current prescribing practice for each partic-
ipating clinician. It was anticipated, before the trial, that the use
of the TPMT test would encourage clinicians to conﬁdently start
azathioprine at a treatment dose earlier in the patients’ treat-
ment plan rather than the current practice of slow titrating up
from a low start dose, with frequent monitoring of blood results
to reduce the risk of adverse effects, such as neutropenia, from
developing [2]. In the TPMT testing arm, because the trial was
pragmatic in design, it attempted to establish whether genotyp-
ing altered clinicians’ prescribing behavior and it was found that
clinicians were initiating treatment at a lower dose for TPMT
heterozygotes as advised by the genotype result. Overall, there
was no difference between the prescribing dose patterns of
azathioprine between initiation and at 4 months between the
two arms of the RCT, which indicated that clinicians were not
following the recommendations in the clinical test report. In a
subsequent article by Thompson et al. (manuscript in prepara-
tion), the impact of the TPMT test compared with that of the
current practice was measured by using the EuroQol ﬁve-
dimensional questionnaire and a small negative difference in
health status in the genotype arm was observed, which may have
been a reﬂection of the lack of adherence to test recommenda-
tions, which subsequently manifest as a small detrimental effect
on health beneﬁt from testing [21]. The TARGET study was
underpowered to detect a statistical difference in health status
between the two arms, but a positive change in health would
have been predicted for the TPMT test arm. Several observations
can be made from this study. It was apparent that clinicians were
not changing their prescribing behavior, which might have been a
consequence of a perceived lack of conﬁdence in using the TPMT
test. Clinicians, like decision makers working at a policy level,
require robust evidence of potential effect of using a companion
diagnostic test before modifying their current prescribing behav-
ior. Furthermore, this trial was one of the very few prospective
randomized studies of a pharmacogenetic test, which resulted in
moderate evidence of a modest effect of using TPMT to inform
prescribing behavior and reduce the risk of neutropenia. The trial
required extensive expense, time, and effort to conduct and yet
still resulted in a smaller sample size than planned, which meant
that the robustness of the ﬁndings was minimal. There is a
continued demand, however, for prospective trials to support the
introduction of personalized medicines at the national, local, and
individual patient level. The feasibility of meeting this demand
for RCT evidence is questionable, given available funding resour-
ces and research effort.
Evidence of the clinical effectiveness and cost-effectiveness of
a companion diagnostic medicine is a necessary but not sufﬁ-
cient requirement for the fully informed introduction and use of
the technology in clinical practice. It is also necessary to consider
how to develop patient-centered services so that maximum
patient beneﬁt is achieved. A qualitative literature is nowemerging that focuses on clinicians’ and patients’ views and
expectations of personalized medicine, which can be useful to
begin to understand the implications of companion diagnostic
medicines for models of health service delivery. Clinicians
involved in the delivery of companion diagnostic-medicine serv-
ices can represent a range of health care disciplines, and other
health care professionals, such as pharmacists, nurses, and
clinical scientists, may also have a role. Fargher et al. [15]
conducted semi-structured interviews with patients who had
been prescribed azathioprine and therefore potentially at risk of
neutropenia that could be averted by using the TPMT test, as well
as focus groups with a range of clinicians. This study identiﬁed
no current models of service delivery for pharmacogenetic tests,
but a clear preference from patients for information from appro-
priately qualiﬁed clinicians who can explain the purpose of the
tests and implications of the results. None of the clinicians
involved in the study, representing disciplines such as genetics,
general medicine, laboratory medicine, nursing, and pharmacy,
stated that they felt a clear responsibility for the delivery of
pharmacogenetic services. This study, therefore, identiﬁed a clear
gap between patients’ expectations for information and clini-
cians’ perceptions regarding who is responsible for providing this
information to patients. This ﬁnding was echoed in subsequent
qualitative studies exploring the views of genetic counselors and
geneticists who currently have a role in the provision of infor-
mation to patients about genetic tests but not speciﬁcally com-
panion genetic diagnostic tests, such as pharmacogenetic tests.
Two qualitative studies have speciﬁcally aimed to understand
whether, and how, genetic specialists perceive they have a role in
the context of pharmacogenetic service delivery and have con-
cluded that the most workable model of service delivery would be
to use genetic counselors or geneticists in a specialist advisory
role within a multidisciplinary clinic [22,23]. An important gen-
eral ﬁnding from these studies was that models of service
delivery and associated evidence requirements to support their
development are likely to be dependent on the particular type of
companion diagnostic. A service delivery model for a companion
diagnostic in oncology will differ from an application in general
medicine or the primary care setting. Furthermore, current
examples of companion diagnostics are speciﬁc to one medicine
but there is already the potential for genetic proﬁling and
targeting of more than one medicine by using the results of one
test. It is clear that patients’ and clinicians’ preferences and
expectations of a service offering a genetic proﬁle will be quite
different from those of a single diagnostic-medicine combination.
A commonality for any type of test is, however, likely to be the
extent of information patients expect from clinicians. A stated
preference study using a discrete choice experiment to compare
patients’ and clinicians’ preferences for how best to deliver a
pharmacogenetic testing service for TPMT identiﬁed a mismatch
between patients’ expectations for information and clinicians’
views on the importance of information relative to other attrib-
utes such as test effectiveness [24]. This small but emerging
evidence base on how to deliver personalized medicine as part of
a health care service shows particular challenges of, and need for
supportive information on, how best to meet patient information
needs while balancing the use of clinicians’ time and expertise to
deliver a busy health care service.
Summary of Recommendations for Europe
Personalized medicine is moving into clinical practice in much
the same way as most other innovations in health care: in a slow
and haphazard manner with few examples of an evidence-based
approach to market access. A large number of commentators
have already reported a need to plan an effective and controlled
strategy for the managed introduction of personalized medicine
Table 2 – Example recommendations for working
toward market access for companion diagnostic
medicines in Europe.
Recommendation Possible approach Timescale
To understand the
current use of HTA
to inform
reimbursement and
payer decisions for
companion
diagnostic
medicines across
Europe
Structured document
review supported
by a survey of key
stakeholders
Short term
To identify and create
a database of
existing
reimbursement and
payer systems for
diagnostics and
medicines across
Europe
Structured document
review supported
by a survey of key
stakeholders
Short term
To identify how
companion
diagnostics are
priced and/or
charged for at the
provider level across
Europe
Survey of providers in
hospitals and
service
commissioners
Short term
To understand the
extent of variation
in technologies and
processes for the
conduct of
companion
diagnostic testing
within and across
Europe
Survey of research
and clinical
laboratories
Short term
To understand how
existing
reimbursement and
payer systems for
diagnostics and
medicines across
Europe must be
realigned to
facilitate market
entry
Semi-structured
interviews and
survey of key
stakeholders
Medium
term
To produce guidance
on the technicalities
of the design and
conduct of the HTA
process speciﬁc to
companion
diagnostic
medicines
Establish a working
group of key HTA
bodies
Medium
term
To understand the
implications of
moving from single
companion
diagnostics to
multiple proﬁles for
evidence
requirements and
service provision
Semi-structured
interviews and
survey of key
stakeholders
Medium
term
Table 2 – continued
Recommendation Possible approach Timescale
To identify incentives
to encourage
manufacturers to
invest in the
production of a
robust evidence
base supporting the
clinical
effectiveness and
cost-effectiveness of
companion
diagnostic
medicines
Establish a mixed
working group of
key HTA bodies
and manufacturers
Medium to
long
term
To describe and
quantify gaps in the
evidence base and
the added value of
future research to
reduce current
uncertainties to
support the
introduction of
companion
diagnostics
Economic modeling
with formal value
of information
methods
Medium
term
To identify and target
national funding for
research to
understand the
added value of
technologies
Establish a working
group of HTA
bodies and
research funding
bodies
Medium to
long
term
To align the use of
HTA for the
reimbursement of
companion
diagnostics in line
with existing
practice for
medicines
Establish a working
group of key HTA
bodies
Long term
To produce clear and
explicit guidance on
the evidence that
decision makers
working at national
and local provider
levels would like to
support the
reimbursement of
companion
medicine
diagnostics
Establish a mixed
working group of
key stakeholders
including HTA
bodies,
manufacturers,
and hospital
providers
Long term
HTA, health technology assessment.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) S 3 2 – S 3 8 S37into clinical practice. Organizations and working groups have
also been established to focus on producing recommendations
for the key evidence requirements and strategic approaches
reimbursement agencies/payers need to consider and ensure
the effective, safe, and cost-effective entry of personalized med-
icines into the market for health care. The European Personalised
Medicine Association [25] is one example of an organization with
a remit “to provide a pro-active platform for the harmonisation of
personalised medicine development and implementation across
Europe by providing a centralised point of contact for the relevant
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) S 3 2 – S 3 8S38stakeholders.” The European Personalised Medicine Association
also has a speciﬁc Health Economic Policy and Reimbursement
Committee that has produced a list of recommendations to focus
on the evidence-based introduction of personalized medicine.
Another body, the Personalised Medicine Coalition, has also
produced working papers that summarize the need to reevaluate
existing assessment and payment systems to meet the growing
number of personalized medicine technologies that are brought
to the market and take a structured and coordinated approach to
ensuring market access across Europe [26]. The degree of success
of these organizations and bodies in achieving the aim of
strategically implementing ever-developing technologies is not
known and may perhaps never be known. Furthermore, sub-
stantial organizational, ﬁnancial, clinical, and practical barriers
exist to taking a strategic approach within an individual country’s
health care system let alone across a group of countries such as
Europe. Taking a collective view of the existing literature—both
published (see, e.g., Reference 10) and available from publicly
available Web sites (see, e.g., References 25 and 27), it is possible
to identify some commonalities in the existing recommenda-
tions, which seem to be reasonable starting points to achieve a
strategic approach toward market access for companion diag-
nostic medicines in European countries. Table 2 summarizes an
example list of such recommendations, with proposed time-
scales, which we believe must be met to achieve a strategic
approach to market access for personalized medicines in Europe
such that potential patient beneﬁts are maximized, given the
resources available.Conclusions
This article has reﬂected on the existing literature considering
how to achieve market access for personalized medicine in
general and companion diagnostic medicines in particular in
Europe. The clear driver for successful market access is the
generation of a suitably robust evidence base for good decision
making such that health care resources are used for the max-
imum beneﬁt of personalized medicines prescribed to the
patients. The development of a suitable evidence base needs to
take account of the perspectives of the different stakeholders and
the levels of decision making within a health care system. Some
recommendations for developing an evidence base have been
suggested together with possible approaches and necessary
timescales. The key question for reimbursement and payers is
to decide whether they trust that the evidence base is sufﬁcient
for “informed” decision making and resource allocation.
Source of ﬁnancial support: ISPOR provided a modest
honorarium.
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